Treace Medical to acquire RPM-3D assets for up to $30M; patient-specific guides for foot surgery

TREACE MEDICAL CONCEPTS, INC.

$20M upfront cash plus up to $10M milestone payments for RPM-3D's pre-op planning and patient-specific guides.
FDA-cleared technology to integrate with Lapiplasty and Adductoplasty; commercial launch expected H2 2024.
Acquisition includes 22 patent applications to strengthen IP portfolio for bunion and foot deformity correction.
RPM-3D uses CT scan data for 3D pre-operative planning and 3D-printed patient-specific cut guides.
Transaction follows recent product launches; direct sales force to market new technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.